Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome
Status:
RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).